



3415A 3 Ave NW, Calgary, Alberta, T2N 0M4, Canada

**Patient Name:** PATIENT, NAME**Specimen ID (SID):** 26001-0000-04**DOB:** 01-Jan-2000**PHN:** AB 00000000**Reason for Testing:** Encephalitis**Relevant Medications:** -**External SID:** 123456789**Doctor:** Dr. Doctor**Report Date:** 27-Mar-2026**Specimen Type:** CSF**Date/Time Collected:** 01-Jan-2026 / 00:00**Cytokine, Chemokine & Growth Factor Panel****Laboratory Developed Test (LDT)****Report Summary:****Sample Comments:**

-

Results Summary:**High Analytes:** APRIL, IL-16, IL-17F, IL-31, IL-35, MIP-3 α , MPIF-1, sCD137**High Normal Analytes:** HMGB1, I-309, IL-18**Low Normal Analytes:** SDF-1**Low Analytes:** ENA-78, Granzyme A, MCP-2, MIP-3 β , SCF, TRAIL**Results Interpretation:****Profile Overview:**

- The results suggest possible B-cell survival and co-stimulatory signaling, supported by high APRIL and sCD137, which may reflect an environment favoring B-cell support or activation.
- Cytotoxic and apoptosis-related effector signaling may be diminished, as indicated by low Granzyme A and TRAIL, which could reflect reduced cytotoxic or apoptotic activity.
- Chemokine-mediated cellular recruitment patterns are evident, with signals that may favor lymphocyte trafficking-including high MIP-3 α and high normal I-309-while low ENA-78, MCP-2, and MIP-3 β suggest reduced recruitment of neutrophils and monocytes/macrophages. High MPIF-1 may indicate a role in inflammatory amplification. Low normal SDF-1 could reflect altered homeostatic trafficking.

Disclaimer:

The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.

Reviewed by: DP**Eve Technologies Corporation is a CLIA certified High Complexity International Laboratory**



3415A 3 Ave NW, Calgary, Alberta, T2N 0M4, Canada

**PATIENT, NAME**

PHN: AB 00000000; DOB: 01-Jan-2000; SID: 26001-0000-04; External SID: 123456789

Cytokine, Chemokine & Growth Factor Panel**Laboratory Developed Test (LDT)**

Analyte	Results (pg/ml)	Reference Interval†	Analyte	Results (pg/ml)	Reference Interval†
6CKine*	< 293	0 - 293	IL-20	10.2	4.1 - 36.0
APRIL	1597 HIGH	160 - 562	IL-21	4.2	0 - 6.7
BAFF	266	122 - 345	IL-22*	< 16.0	0 - 16.0
BCA-1	< 0.9	0 - 2.7	IL-23*	< 97.7	0 - 97.7
CCL28*	< 122	0 - 122	IL-24*	< 24.4	0 - 24.4
CTACK*	< 7.3	0 - 7.3	IL-27	57.8	0 - 250
EGF*	< 4.0	0 - 4.0	IL-28A*	< 9.8	0 - 9.8
ENA-78	1.9 LOW	3.9 - 13.4	IL-29*	< 12.2	0 - 12.2
Eotaxin	< 4.0	0 - 5.5	IL-31*	3.5 HIGH	0 - 1.2
Eotaxin-2	4.5	0 - 8.0	IL-33*	< 19.5	0 - 19.5
Eotaxin-3	1.8	0 - 3.8	IL-34	11.0	6.3 - 38.4
FGF-2	< 16.0	0 - 20.3	IL-35*	25.4 HIGH	0 - 24.4
FLT-3L	2.1	0 - 17.2	IP-10	89.2	15 - 1854
Fractalkine	28.7	0 - 73.1	I-TAC	< 1.2	0 - 7.6
GCP-2	2.1	0.2 - 8.7	LIF*	< 2.4	0 - 2.4
G-CSF*	< 6.0	0 - 6.0	Lymphotactin*	< 29.3	0 - 29.3
GM-CSF	< 3.2	0 - 3.9	MCP-1	189	86 - 1661
Granzyme A	4.8 LOW	7.7 - 34.9	MCP-2	0.4 LOW	0.4 - 3.4
Granzyme B	1.2	0 - 2.0	MCP-3	< 2.5	0 - 4.4
GRO α	5.4	0 - 15.6	MCP-4*	< 1.7	0 - 1.7
HMGB1	785	0 - 861	M-CSF	132	0 - 283
I-309	4.9	1.5 - 6.0	MDC	5.5	0 - 10.4
IFN- α 2	< 2.5	0 - 3.7	MIG	10.1	0 - 173
IFN β *	< 4.9	0 - 4.9	MIP-1 α *	< 2.0	0 - 2.0
IFN γ	< 0.2	0 - 0.4	MIP-1 β	1.9	0 - 8.4
IFN ω *	< 2.4	0 - 2.4	MIP-1 δ	78.8	30 - 252
IL-1 α *	< 3.0	0 - 3.0	MIP-3 α	0.3 HIGH	0 - 0.2
IL-1 β	< 2.0	0 - 3.7	MIP-3 β	16.8 LOW	16.9 - 77.0
IL-1RA	1.4	0 - 3.6	MPIF-1	20.3 HIGH	1.1 - 19.7
IL-2*	< 0.4	0 - 0.4	PDGF-AA	27.6	7 - 127
IL-3*	< 0.4	0 - 0.4	PDGF-AB/BB*	< 12.0	0 - 12.0
IL-4	< 0.1	0 - 0.1	Perforin	< 18.3	0 - 26.0
IL-5	0.5	0.3 - 2.8	RANTES	1.0	0 - 10.6
IL-6	5.0	0 - 8.5	sCD137	1.5 HIGH	0 - 1.3
IL-7*	< 0.4	0 - 0.4	sCD40L	6.0	0 - 8.3
IL-8	39.8	5.5 - 68.2	SCF	35.1 LOW	76 - 429
IL-9	3.7	0 - 11.0	SDF-1	889	837 - 6392
IL-10	0.5	0 - 3.3	sFas (ng/ml)	1.2	0.6 - 3.2
IL-11	< 1.2	0 - 1.8	sFasL	25.7	8.6 - 35.2
IL-12p40	4.0	0 - 9.7	TARC	0.7	0 - 2.0
IL-12p70*	< 1.0	0 - 1.0	TGF α	2.0	0 - 5.7
IL-13*	< 4.0	0 - 4.0	TNF α	1.8	0 - 4.5
IL-15	9.1	2.2 - 15.6	TNF β *	< 1.0	0 - 1.0
IL-16	34.2 HIGH	4.9 - 33.5	TPO	9.8	0 - 61.0
IL-17A*	< 0.8	0 - 0.8	TRAIL	< 1.2 LOW	1.3 - 4.1
IL-17E/IL-25	< 1.6	0 - 3.0	TSLP	< 0.5	0 - 0.7
IL-17F*	2.9 HIGH	0 - 2.1	VEGF-A*	< 0.8	0 - 0.8
IL-18	0.8	0 - 1.0			

† Reference intervals estimated by data-mining ≥ 200 CSF samples drawn from both healthy and pathological subjects.

* Upper reference limit defined as the lower limit of quantification (LLOQ) for this analyte.